Publications
Showing 1 - 100 results of 6,418 publications
2025
- AGA Living Clinical Practice Guideline on Computer-Aided Detection–Assisted ColonoscopySultan S, Shung D, Kolb J, Foroutan F, Hassan C, Kahi C, Liang P, Levin T, Siddique S, Lebwohl B. AGA Living Clinical Practice Guideline on Computer-Aided Detection–Assisted Colonoscopy. Gastroenterology 2025, 168: 691-700. PMID: 40121061, DOI: 10.1053/j.gastro.2025.01.002.
- Socioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region.Al Ta'ani O, Al-Ajlouni Y, Lahoud C, Almasaid S, Alhalalmeh Y, Oweis Z, Danpanichkul P, Baidoun A, Alsakarneh S, Dahiya DS, Njei B. Socioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region. Int J Equity Health 2025, 24: 85. PMID: 40148874, DOI: 10.1186/s12939-025-02448-9.
- Ulcerative colitis and bullous pemphigoid: Direct association or a medication side effect: A case report.Haddad G, El Dada A, Sbeih S, Kazzi T, Karam K, Chaptini L. Ulcerative colitis and bullous pemphigoid: Direct association or a medication side effect: A case report. World Journal Of Clinical Cases 2025, 13: 101363. PMID: 40144487, PMCID: PMC11670022, DOI: 10.12998/wjcc.v13.i9.101363.
- Moderate alcohol-associated hepatitis: A real-world multicenter studyIdalsoaga F, Díaz L, Dunn W, Mehta H, Muñoz K, Caldentey V, Arnold J, Ayares G, Mortuza R, Sarin S, Maiwall R, Zhang W, Qian S, Simonetto D, Singal A, Elfeki M, Ramirez-Cadiz C, Malhi G, Ahmed A, Homsi H, Abid Z, Cabezas J, Echavarría V, Poca M, Soriano G, Cuyas B, Cots M, La Tijera M, Ayala-Valverde M, Perez D, Gomez J, Abraldes J, Al-Karaghouli M, Jalal P, Ibrahim M, García-Tsao G, Goyes D, Skladaný L, Havaj D, Sulejova K, Selcanova S, Rincón D, Chacko K, Restrepo J, Yaquich P, Toro L, Shah V, Arrese M, Kamath P, Bataller R, Arab J. Moderate alcohol-associated hepatitis: A real-world multicenter study. Hepatology Communications 2025, 9: e0673. PMID: 40131003, PMCID: PMC11936654, DOI: 10.1097/hc9.0000000000000673.
- Liver Traffic Jam: How Sinusoidal Congestion Rewires Macrophage Distribution via CXCL9Iwakiri Y. Liver Traffic Jam: How Sinusoidal Congestion Rewires Macrophage Distribution via CXCL9. Cellular And Molecular Gastroenterology And Hepatology 2025, 101492. PMID: 40132660, DOI: 10.1016/j.jcmgh.2025.101492.
- BCL2 inhibition for multiple myeloma and AL amyloidosisCani L, Gupta V, Kaufman J. BCL2 inhibition for multiple myeloma and AL amyloidosis. British Journal Of Haematology 2025 PMID: 40090369, DOI: 10.1111/bjh.20046.
- High Risk of Persistence and Risk of Dysplasia after Ultrashort Barrett's Diagnosis.Skef W, Haydel J, Rao A, Allencherril R, George R, Ketwaroo G, Thrift A, El-Serag H, Wenker T. High Risk of Persistence and Risk of Dysplasia after Ultrashort Barrett's Diagnosis. The American Journal Of Gastroenterology 2025 PMID: 40052679, DOI: 10.14309/ajg.0000000000003383.
- Eosinophilic esophagitis manifesting as intractable hiccups in an elderly patient: a case reportJalloul S, Salem J, Karam K, Chamoun C, Chaptini L. Eosinophilic esophagitis manifesting as intractable hiccups in an elderly patient: a case report. Journal Of Medical Case Reports 2025, 19: 99. PMID: 40045389, PMCID: PMC11884032, DOI: 10.1186/s13256-025-05044-1.
- Medical foundation large language models for comprehensive text analysis and beyondXie Q, Chen Q, Chen A, Peng C, Hu Y, Lin F, Peng X, Huang J, Zhang J, Keloth V, Zhou X, Qian L, He H, Shung D, Ohno-Machado L, Wu Y, Xu H, Bian J. Medical foundation large language models for comprehensive text analysis and beyond. Npj Digital Medicine 2025, 8: 141. PMID: 40044845, PMCID: PMC11882967, DOI: 10.1038/s41746-025-01533-1.
- Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and ManagementSobani, Z.A., Hung, K.W. Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and Management. Curr Treat Options Gastro 23, 4 (2025). https://doi.org/10.1007/s11938-025-00469-5
- Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and ManagementSobani Z, Hung K. Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and Management. Current Treatment Options In Gastroenterology 2025, 23: 4. DOI: 10.1007/s11938-025-00469-5.
- Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot StudyTefera J, Kuhn T, Matuschewski N, Meister E, Nguyenová J, Kao T, Mutonga M, Bitar R, Kahl V, Zhang X, Shewarega A, Chapiro J, Madoff D. Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. Journal Of Vascular And Interventional Radiology 2025 PMID: 40043833, DOI: 10.1016/j.jvir.2025.02.028.
- The Educational Impact of the GI Hospitalist Model on Gastroenterology Fellowship Training.Flanagan R, Levine C, Hung K, Hughes M, Fritz CDL, Wan D, Stein DJ. The Educational Impact of the GI Hospitalist Model on Gastroenterology Fellowship Training. Gastroenterology 2025, 168: 450-453.e2. PMID: 39366469, DOI: 10.1053/j.gastro.2024.09.028.
- No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma among Treatment Naïve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted AnalysisYang Z, Cheung R, Jou J, Lim J, Wong R. No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma among Treatment Naïve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted Analysis. Journal Of Clinical And Experimental Hepatology 2025, 102540. DOI: 10.1016/j.jceh.2025.102540.
- BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMABDubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Inflammatory Bowel Diseases 2025, 31: s62-s63. DOI: 10.1093/ibd/izae282.147.
- Eliglustat substrate reduction therapy in children with Gaucher disease type 1Ain N, Saith A, Ruan A, Yang R, Burton A, Mistry P. Eliglustat substrate reduction therapy in children with Gaucher disease type 1. Frontiers In Pediatrics 2025, 13: 1543136. PMID: 40083427, PMCID: PMC11903696, DOI: 10.3389/fped.2025.1543136.
- Mapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals’ Perspective: A Cross-Sectional Non-Interventional StudyAzzam N, Mosli M, Almutairdi A, Alghamdi M, Meeralam Y, Alolimi K, Arsalan M, Al-Bawardy B. Mapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals’ Perspective: A Cross-Sectional Non-Interventional Study. Journal Of Clinical Medicine 2025, 14: 1621. PMID: 40095549, PMCID: PMC11899997, DOI: 10.3390/jcm14051621.
- Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACEKasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.
- Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Taddei T, Brown D, Yarchoan M, Mendiratta-Lala M, Llovet J. Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2025 PMID: 39992051, DOI: 10.1097/hep.0000000000001269.
- The Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis.McCarty TR, Shah R, Allencherril RP, Moon N, Njei B. The Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2025 PMID: 39998988, DOI: 10.1097/MCG.0000000000002148.
- Colorectal Neoplasia in Inflammatory Bowel DiseaseAl Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B. Colorectal Neoplasia in Inflammatory Bowel Disease. Cancers 2025, 17: 665. PMID: 40002259, PMCID: PMC11853504, DOI: 10.3390/cancers17040665.
- Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisNair R, Vu A, Freer A, Bhatia K, Wang D, Savani M, Matulis S, Lonial S, Jaye D, Boise L, Seo S, Corson T, Nooka A, Bhatt S, McBrayer S, Gupta V, Hu X, Barwick B, Reddi A, Shanmugam M. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 2025, 145: 732-747. PMID: 39693611, DOI: 10.1182/blood.2024025690.
- Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myelomaPotdar S, Kapadia S, Azeem M, Radzievski R, Lakhani K, Joseph N, Kaufman J, Hofmeister C, Gupta V, Lonial S, Nooka A, Dhodapkar K, Dhodapkar M. Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood Advances 2025 PMID: 39913930, DOI: 10.1182/bloodadvances.2024015680.
- Sex-based Influences on White Matter Tract Integrity in Alcohol Use Disorder: a Systematic ReviewBarrios N, Nartey N, Yue J, Riordan W, Kohler R, Verplaetse T, Roberts W, Carretta R, Banini B, Zhou H, Garcia-Rivas V, Blackford J, Zakiniaeiz Y. Sex-based Influences on White Matter Tract Integrity in Alcohol Use Disorder: a Systematic Review. Current Addiction Reports 2025, 12: 10. DOI: 10.1007/s40429-025-00624-z.
- Molecular cell atlas of the brain in neuronopathic Gaucher diseaseNair S, Mehta S, Belinsky G, Mistry P. Molecular cell atlas of the brain in neuronopathic Gaucher disease. Molecular Genetics And Metabolism 2025, 144: 108868. DOI: 10.1016/j.ymgme.2024.108868.
- Investigating the genomic basis of phenotypic diversity among siblings in Gaucher diseaseAin N, Kulkarni N, Ruan J, Ruan A, Nair S, Mehta S, Mistry P. Investigating the genomic basis of phenotypic diversity among siblings in Gaucher disease. Molecular Genetics And Metabolism 2025, 144: 108633. DOI: 10.1016/j.ymgme.2024.108633.
- Apoe-Abca1 axis is involved in the pathogenesis of Gaucher diseaseXing S, Nair S, Mistry P. Apoe-Abca1 axis is involved in the pathogenesis of Gaucher disease. Molecular Genetics And Metabolism 2025, 144: 108987. DOI: 10.1016/j.ymgme.2024.108987.
- Long-term outcomes of imiglucerase treatment in children with Gaucher disease type 1 or type 3 starting therapy before the age of 2 yearsMistry P, Carwile J, Burrow A, Ganesh J, Camelo J, Hennermann J, Batista J, Oliveira-dos-Santos A, Perichon M, Tantawy A. Long-term outcomes of imiglucerase treatment in children with Gaucher disease type 1 or type 3 starting therapy before the age of 2 years. Molecular Genetics And Metabolism 2025, 144: 108858. DOI: 10.1016/j.ymgme.2024.108858.
- BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMABDubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Gastroenterology 2025, 168: s88-s89. DOI: 10.1053/j.gastro.2025.01.212.
- Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.Serper M, Tang H, Zhang S, McCullough A, Kaplan D, Taddei T, Mahmud N. Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study. Hepatology 2025 PMID: 39879583, DOI: 10.1097/hep.0000000000001251.
- Reply to Li et al, Ren et al, Raghareutai and Kaosombatwattana, and Zhang et alShung D. Reply to Li et al, Ren et al, Raghareutai and Kaosombatwattana, and Zhang et al. Gastroenterology 2025 PMID: 39884466, DOI: 10.1053/j.gastro.2025.01.016.
- Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLSAllegretti J, Feuerstadt P, Knapple W, Orenstein R, Pinton P, Sheh A, Khanna S. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases 2025, izae291. PMID: 39862395, DOI: 10.1093/ibd/izae291.
- Diagnosis and Management of Acute PancreatitisMittal N, Oza V, Muniraj T, Kothari T. Diagnosis and Management of Acute Pancreatitis. Diagnostics 2025, 15: 258. PMID: 39941188, PMCID: PMC11816589, DOI: 10.3390/diagnostics15030258.
- P1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional studyAzzam N, Mosli M, Almutairdi A, Alghamdi M, Meeralam Y, Alolimi K, Arsalan M, Al-Bawardy B. P1216 Mapping the Ulcerative Colitis patient journey in Saudi Arabia from healthcare professionals' perspective: A cross-sectional non-interventional study. Journal Of Crohn's And Colitis 2025, 19: i2198-i2200. DOI: 10.1093/ecco-jcc/jjae190.1390.
- P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel DiseaseAlmuhaya H, Alashkar R, Alsebaai D, Albadawi N, Almutairdi A, Attamimi M, Desai S, Al-Bawardy B. P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease. Journal Of Crohn's And Colitis 2025, 19: i951-i951. DOI: 10.1093/ecco-jcc/jjae190.0616.
- P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) StudyShehab M, Azzam N, Al-Bawardy B, Abid S, Bashandi A, AlShihri R, Mukhtar M, Saadah O, Alharbi O, Al-Darmaki A, Al Harthi S, Al-Ejji K, Ayash A, Al sahli A, Khamees N, Salem O, Mohamed E, Maher M, Daba G, Helal A, Alnassar M, Alfadhli A, Mosli M. P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study. Journal Of Crohn's And Colitis 2025, 19: i2280-i2281. DOI: 10.1093/ecco-jcc/jjae190.1434.
- ReplyPatel A, Laine L, Moayyedi P. Reply. Gastroenterology 2025, 168: 849-850. PMID: 39848603, DOI: 10.1053/j.gastro.2025.01.001.
- Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.John B, Bastaich D, Mezzacappa C, Ferreira R, Hentschel A, Samos A, Mahmud N, Taddei T, Kaplan D, Serper M, Dahman B. Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal Of Gastroenterology 2025 PMID: 39950372, DOI: 10.14309/ajg.0000000000003321.
- Practices and perspectives of genetic counselors about high‐risk pancreatic cancer screening: A cross‐sectional survey studyWiegand A, Chhoda A, Namboodiri A, Grimshaw A, Dalela D, Farrell J. Practices and perspectives of genetic counselors about high‐risk pancreatic cancer screening: A cross‐sectional survey study. Journal Of Genetic Counseling 2025, 34: e2016. PMID: 39814542, DOI: 10.1002/jgc4.2016.
- AGA Institute Quality Indicator Development for Irritable Bowel SyndromeHung K, Leiman D, Kaza A, Watson R, Chang L, Maratt J, Committee A. AGA Institute Quality Indicator Development for Irritable Bowel Syndrome. Gastroenterology 2025, 168: 612-622.e4. PMID: 39818650, DOI: 10.1053/j.gastro.2024.11.003.
- Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysisSannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.
- Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort StudyNjei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.
- The evolving role of liver biopsy: Current applications and future prospectsGopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.
- Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individualsMistry P, Cassiman D, Jones S, Lachmann R, Lukina E, Prada C, Wasserstein M, Thurberg B, Foster M, Patel R, Underhill L, Peterschmitt M. Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals. Hepatology Communications 2025, 9: e0621. PMID: 39774103, PMCID: PMC11717527, DOI: 10.1097/hc9.0000000000000621.
- Contributors for Volume 2Agarwal A, Al lami Z, Ala A, Anand A, Anirvan P, Arab J, Bagwan I, Bahure U, Baloji A, Bataller R, Batsis I, Behera M, Berlinrut I, Bhamidimarri K, Bhongade M, Bhujade H, Bucuvalas J, Chayanupatkul M, Clemente-Sanchez A, Cussen C, De A, Dieterich D, DiNorcia J, Dunn W, Duseja A, Sabagh A, Talkhan M, Em M, Gupta S, Huisman T, Ilyas F, Jain S, Jalal P, Kalra N, Kamani L, Khandelwal R, Khuroo M, Khuroo N, Kim E, Yin J, Maiwall R, Mallakmir S, Mehta H, Mohamed I, Molmenti A, Molmenti E, Nagral A, Nair V, Odin J, Panigrahi M, Polanco N, Prachanronarong K, Praharaj D, Raja K, Satapathy S, Schiano T, Schilsky M, Singal A, Singh S, Smith R, To U, Vanatta J, Wallach F, ZainAloor F. Contributors for Volume 2. 2025, xxv-xxix. DOI: 10.1016/b978-0-443-26711-6.09992-3.
- Chapter 30 Wilson disease⊛To U, Schilsky M. Chapter 30 Wilson disease⊛. 2025, 841-859. DOI: 10.1016/b978-0-443-26711-6.00030-5.
- Liver Fibrosis and Cardiovascular Events.Nso N, Bookani KR, Trimingham M, Orji R, Njei B, Balasubramanian SS, Pursnani A. Liver Fibrosis and Cardiovascular Events. South Med J 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/SMJ.0000000000001769.
- Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.Al-Bawardy B, Quraishi M. Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848251328606. PMID: 40144790, PMCID: PMC11938434, DOI: 10.1177/17562848251328606.
- Cirrhosis and Truly Elective Major SurgeryJakab S, Oprea A. Cirrhosis and Truly Elective Major Surgery. 2025, 249-258. DOI: 10.1093/med/9780190902001.003.0021.
2024
- US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020Banini B, Chauhan S, Amatya A, Dashti F, Zahrawi K, Zahrawi F, Mehal W, McKee S. US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020. Alcohol Clinical And Experimental Research 2024, 49: 358-367. PMID: 39739407, DOI: 10.1111/acer.15515.
- Performance of Ulcer Features in Predicting Malignancy Among Gastric Ulcers Diagnosed on Upper Endoscopy.Patel A, Gandle C, Baerman E, Lill I, Pecha R, Nguyen Wenker T, El-Serag H, Ketwaroo G, Tan M. Performance of Ulcer Features in Predicting Malignancy Among Gastric Ulcers Diagnosed on Upper Endoscopy. Journal Of Clinical Gastroenterology 2024 PMID: 39761160, DOI: 10.1097/mcg.0000000000002118.
- Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐AnalysisGiannini E, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M. Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International 2024, 45: e16222. PMID: 39720853, PMCID: PMC11669080, DOI: 10.1111/liv.16222.
- Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy SupportGottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.
- Impact of Fatigue on Work Productivity, Activity Impairment, and Healthcare Resource Utilization in Inflammatory Bowel DiseaseFeagins L, Moore P, Crabtree M, Eliot M, Lemay C, Loughlin A, Gaidos J. Impact of Fatigue on Work Productivity, Activity Impairment, and Healthcare Resource Utilization in Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 7: otae073. PMID: 39742035, PMCID: PMC11684069, DOI: 10.1093/crocol/otae073.
- PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progressHayes C, Gallucci G, Boyer J, Assis D, Ghonem N. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. Hepatology Communications 2024, 9: e0612. PMID: 39699308, PMCID: PMC11661771, DOI: 10.1097/hc9.0000000000000612.
- Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.Vutien P, Barnard Giustini A, Kim N, Moon A, Hsu C, Mezzacappa C, Borgerding J, Johnson K, VoPham T, Berry K, Beste L, Kaplan D, Taddei T, Ioannou G. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology 2024 PMID: 39689352, DOI: 10.1097/hep.0000000000001183.
- Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosisMezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39689774, DOI: 10.1016/j.cgh.2024.10.035.
- Validation of the NCCN/Yale criteria for the identification of CDH1 pathogenic variant carriersLerner B, Giner-Calabuig M, Carraway C, Richardson M, Krahn K, Susswein L, Nielsen S, Karam R, Xicola R, Llor X. Validation of the NCCN/Yale criteria for the identification of CDH1 pathogenic variant carriers. Journal Of Medical Genetics 2024, 62: 57-61. PMID: 39674581, PMCID: PMC11916899, DOI: 10.1136/jmg-2024-110446.
- Non-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosisWong Y, Buckholz A, Sim A, Teng M, Wong R, Curry M, De Roza M, Baffy G, Teoh X, Chak E, Rustagi T, Chang J, Wong G, Tandon P, Garcia-Tsao G, Abraldes J, Mohanty A, Fortune B. Non-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39675401, DOI: 10.1016/j.cgh.2024.10.022.
- Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease StatusRe V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.
- A bibliometric analysis of inflammatory bowel disease research in the Arab world.AlMuhaidib S, Bzeizi K, AlAmeel T, Mosli M, Khoja B, Barakeh D, Alomaim W, Alqahtani S, Al-Bawardy B. A bibliometric analysis of inflammatory bowel disease research in the Arab world. Saudi Journal Of Gastroenterology 2024 PMID: 39660608, DOI: 10.4103/sjg.sjg_303_24.
- Enhancing Histology Detection in MASH Cirrhosis for Artificial Intelligence Pathology Platform by Expert Pathologist TrainingGoodman Z, Akbary K, Noureddin M, Ren Y, Chng E, Tai D, Boudes P, Garcia‐Tsao G, Harrison S, Chalasani N. Enhancing Histology Detection in MASH Cirrhosis for Artificial Intelligence Pathology Platform by Expert Pathologist Training. Liver International Communications 2024, 5 DOI: 10.1002/lci2.70007.
- Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinomaSantana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma. JHEP Reports 2024, 7: 101294. PMID: 40028344, PMCID: PMC11870164, DOI: 10.1016/j.jhepr.2024.101294.
- Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver MetastasesKuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024, 36: 477-488. PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.
- Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaDutta R, Thibaud S, Leshchenko V, Ram M, Melnekoff D, Bhalla S, Restrepo P, Gupta V, Barwick B, Newman S, McCafferty J, Hantash F, Nooka A, Cho H, Richard S, Rodriguez C, Rossi A, Sanchez L, Chari A, Boise L, Jagannath S, Richter J, Parekh S, Laganà A. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood Neoplasia 2024, 1: 100049. DOI: 10.1016/j.bneo.2024.100049.
- S37 Patients’ Preference and Acceptability of Inflammatory Bowel Diseases Self-Help Interventions: CORE Study (Confidence Optimization through Resources for Education, Engagement, and Empowerment)Sheng E, Lu M, Ostrov A, Burwell S, Shah S, Fiske H, Gaidos J, Forster E, Hunt M, Kuehnel R, Soto C, Weng C, Siegel C, Melmed G, Lewis J, van Deen W, Tse C. S37 Patients’ Preference and Acceptability of Inflammatory Bowel Diseases Self-Help Interventions: CORE Study (Confidence Optimization through Resources for Education, Engagement, and Empowerment). The American Journal Of Gastroenterology 2024, 119: s11-s11. DOI: 10.14309/01.ajg.0001082680.63666.0e.
- The PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancerEarl J, Zogopoulos G, Bi Y, Brand R, Chung D, Farrell J, Graf J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Paiella S, Permuth J, Rosie C, Simeone D. The PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancer. Pancreatology 2024, 24: e82-e83. DOI: 10.1016/j.pan.2024.05.206.
- Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.
- Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver DiseaseBollinger B, Cotter R, Deng Y, Ilagan-Ying Y, Gupta V. Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease. Digestive Diseases And Sciences 2024, 70: 378-385. PMID: 39604664, DOI: 10.1007/s10620-024-08724-y.
- Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites.Wong F, Reddy K, Tandon P, Lai J, Garcia-Tsao G, O'Leary J, Biggins S, Vargas H, Thacker L, Kamath P, Bajaj J. Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites. The American Journal Of Gastroenterology 2024 PMID: 39601412, DOI: 10.14309/ajg.0000000000003251.
- Wilson Disease: Novel Diagnostic and Therapeutic ApproachesMariño Z, Schilsky M. Wilson Disease: Novel Diagnostic and Therapeutic Approaches. Seminars In Liver Disease 2024 PMID: 39496313, DOI: 10.1055/a-2460-8999.
- Corrigendum to: “A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease” [J Hepatol (2022) 765-767]Mehal W, Schwabe R. Corrigendum to: “A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease” [J Hepatol (2022) 765-767]. Journal Of Hepatology 2024, 82: 395. PMID: 39580245, DOI: 10.1016/j.jhep.2024.10.004.
- The Impact of Obesity on the Prevalence and Complications of Perianal Fistulas of Crohn’s DiseaseYoun J, Hsia K, Khadilkar S, Zeina T, Rai P, Rastogi A, Hussani S, Spence S, Adavelly P, Yanes J, Kotlier J, Sweigart B, Levy A, Friedman S. The Impact of Obesity on the Prevalence and Complications of Perianal Fistulas of Crohn’s Disease. Digestive Diseases And Sciences 2024, 70: 323-332. PMID: 39548039, DOI: 10.1007/s10620-024-08729-7.
- Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2024, 84: 3909. PMID: 39544086, DOI: 10.1158/0008-5472.can-24-3017.
- Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trialChey W, Mégraud F, Laine L, Smith N, Leifke E, Hunt B, Howden C. Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial. JGH Open 2024, 8: e70044. PMID: 39554983, PMCID: PMC11567116, DOI: 10.1002/jgh3.70044.
- Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Engel B, Assis D, Bhat M, Clusmann J, Joostrenth, Gerussi A, Londoño M, Oo Y, Schregel I, Sebode M, Taubert R, collaborators T, Diseases T. Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024. JHEP Reports 2024, 7: 101265. PMID: 39897612, PMCID: PMC11783120, DOI: 10.1016/j.jhepr.2024.101265.
- Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.Serper M, Pulaski M, Zhang S, Taddei T, Kaplan D, Mahmud N. Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes. The American Journal Of Gastroenterology 2024 PMID: 39530516, DOI: 10.14309/ajg.0000000000003190.
- Risk of bleeding after percutaneous liver procedures in patients with cirrhosis: Myth or fact?Rabiee A, Rabiee A. Risk of bleeding after percutaneous liver procedures in patients with cirrhosis: Myth or fact? Liver Transplantation 2024, 31: 259-261. PMID: 39526889, DOI: 10.1097/lvt.0000000000000537.
- Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon?Gukovskaya A, Lerch M, Mayerle J, Sendler M, Ji B, Saluja A, Gorelick F, Gukovsky I. Trypsin in pancreatitis: The culprit, a mediator, or epiphenomenon? World Journal Of Gastroenterology 2024, 30: 4417-4438. PMID: 39534420, PMCID: PMC11551668, DOI: 10.3748/wjg.v30.i41.4417.
- Corrigendum to: “From mice to humans: Unravelling the genetic levers of NASH” [J Hepatol (2020) 749-751]Mehal W. Corrigendum to: “From mice to humans: Unravelling the genetic levers of NASH” [J Hepatol (2020) 749-751]. Journal Of Hepatology 2024, 82: 396. PMID: 39516051, DOI: 10.1016/j.jhep.2024.10.002.
- Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese populationDing J, Liu H, Zhang X, Zhao N, Peng Y, Shi J, Chen J, Chi X, Li L, Zhang M, Liu W, Zhang L, Ouyang J, Yuan Q, Liao M, Tan Y, Li M, Xu Z, Tang W, Xie C, Li Y, Pan Q, Xu Y, Cai S, Byrne C, Targher G, Ouyang X, Zhang L, Jiang Z, Zheng M, Sun F, Chai J. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. Science Translational Medicine 2024, 16: eadh9940. PMID: 39504356, DOI: 10.1126/scitranslmed.adh9940.
- Building Clinical and Research Delivery Networks: A Blue Print for Multidisciplinary Management and Consensus in Wilson DiseaseAla A, Yin J, Schilsky M. Building Clinical and Research Delivery Networks: A Blue Print for Multidisciplinary Management and Consensus in Wilson Disease. GE Portuguese Journal Of Gastroenterology 2024, 1-3. DOI: 10.1159/000542402.
- Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last DecadeNajarro G, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Hofmeister C. Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade. Blood 2024, 144: 5142-5142. DOI: 10.1182/blood-2024-202078.
- Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death ReportingHofmeister C, Zhang M, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Sborov D. Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting. Blood 2024, 144: 5152-5152. DOI: 10.1182/blood-2024-202100.
- A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple MyelomaHofmeister C, Gupta V, Kaufman J, Nooka A, Joseph N, Lonial S, Dhodapkar M. A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma. Blood 2024, 144: 255-255. DOI: 10.1182/blood-2024-202102.
- A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe CardiomyopathyHofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.
- Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with VenetoclaxKaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.
- Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two InstitutesVarga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.
- The Role of NOXA in Venetoclax Treatment Response in Multiple MyelomaShivaram S, Yan H, Tang H, Anderson H, Kaddoura M, Wiedmeier-Nutor J, Tian S, Howe M, Bolarinwa A, Zepeda Mendoza C, Gupta V, Lehman S, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Maura F, Kumar S, Baughn L. The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma. Blood 2024, 144: 4635-4635. DOI: 10.1182/blood-2024-205385.
- Risk of Infections in Multiple Myeloma Patients Treated with Bispecific AntibodiesCani L, Scott S, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies. Blood 2024, 144: 3311. DOI: 10.1182/blood-2024-206155.
- Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.
- Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2Matulis S, Chavez R, Owens R, Wiita A, Shanmugam M, De Matos Simoes R, Mitsiades C, Joseph N, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Gupta V, Licht J, Barwick B, Boise L. Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2. Blood 2024, 144: 4663-4663. DOI: 10.1182/blood-2024-210441.
- Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell EngagersAllada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.
- Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.
- Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.
- Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or CirrhosisIlagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.
- The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021.Al Ta'ani O, Al-Ajlouni YA, Aleyadeh W, Al-Bitar F, Alsakarneh S, Saadeh A, Alhuneafat L, Njei B. The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021. Diabetes Obes Metab 2024, 26: 5455-5465. PMID: 39261301, DOI: 10.1111/dom.15924.
- Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology 2024, 313: e232875. PMID: 39560477, PMCID: PMC11605110, DOI: 10.1148/radiol.232875.
- Breaking Ground on the Application of AI to HCC: It's All about Data.Bitar R, Chapiro J. Breaking Ground on the Application of AI to HCC: It's All about Data. Radiology Artificial Intelligence 2024, 6: e240660. PMID: 39601669, PMCID: PMC11605136, DOI: 10.1148/ryai.240660.
- Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.Murnane P, Afshar M, Chamie G, Cook R, Ferguson T, Haque L, Jacobson K, Justice A, Kim T, Khalili M, Krupitsky E, McGinnis K, Molina P, Muyindike W, Myers B, Richards V, So-Armah K, Stewart S, Sulkowski M, Tien P, Hahn J. Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. The American Journal Of Gastroenterology 2024 PMID: 39480054, DOI: 10.14309/ajg.0000000000003178.
